Biogen Inc. (NASDAQ: BIIB ... Viehbacher commented, “So, you know, the race really that we are faced with is seeing the erosion of our multiple sclerosis product revenue. But I'm particularly ...

Biogen has become the latest company to join the race to develop gene editing as a therapy, in a potential $2 billion alliance with the University of Pennsylvania. At the moment, gene editing is ...

Investors with a lot of money to spend have taken a bullish stance on Biogen (NASDAQ ... Options board spots potential market movers before they happen. See what positions big money is taking ...

Biogen forecasts 2025 EPS of $15.25-$16.25, below the $16.34 consensus. Revenue is expected to decline mid-single digits due to MS drug loss Get 5 stock picks identified before their biggest ...

Forecasts 2025 profit below expectations Signs $250 million deal for lupus drug funding Shares drop more than 6% in early trading Feb 12 (Reuters) - Biogen (BIIB.O), opens new tab on Wednesday ...

Biogen Inc.’s stock BIIB tumbled 7% Wednesday, after the biotech beat fourth-quarter earnings estimates but offered guidance that lagged behind consensus, as sales of its multiple sclerosis drug ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

My name is Jennifer, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update.